Regeneron snaps up eye company, snaring science but not staff
Jan 2, 2025 · Regeneron has scooped up Oxular, a retinal-disease-focused company based in the U.K., closing the deal at the very end of 2024. Word of the acquisition was first shared by Oxular’s former CEO ...
Fierce Biotech Layoff Tracker 2025
3 days ago · We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.
Bristol Myers culls cell therapy deals with 2 biotechs
Dec 16, 2024 · Bristol Myers Squibb has terminated cell therapy pacts with two biotechs amid "ongoing portfolio prioritization efforts” within the Big Pharma, one of the affected companies revealed in an SEC ...
mRNA vaccine protects ferrets from current bird flu strain
Dec 18, 2024 · However, these vaccines were designed for past variants of the virus, not the clade causing the current outbreak, known as 2.3.4.4b. The new mRNA vaccine from the CDC and Moderna is specifically ...
Versant-backed Pep2Tango unveils with next-gen obesity ambitions
Nov 21, 2024 · VC firm Versant Ventures is unveiling Pep2Tango Therapeutics, a biotech developing next-gen obesity therapeutics with multiple targets in hopes of overcoming limitations tied to GLP-1 treatments.
Fierce Biotech News & Reports
Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on Fierce Biotech as their must-read source for the latest news, analysis and data in the world of biotech ...
FIRE1 heats up with $120M for its heart failure monitor implant
Jan 7, 2025 · The new funding round—a large step up from its previous $25 million raise in early 2023—was led by Polaris Partners and Patient Square Capital’s Elevage Medical Technologies, and was joined ...
Lawsuit alleges Applied misled investors before FDA rejection
Dec 19, 2024 · After its rare disease drug was rejected by the FDA in late November, Applied Therapeutics vowed to fight on with a resubmission or appeal. But a new lawsuit, filed Dec. 17 in a New York federal ...
Immatics leaps into phase 3 on strength of early-stage PFS data
Oct 10, 2024 · Immatics has vaulted into phase 3 on the strength of early-stage data. The biotech is gearing up to start a pivotal trial of its melanoma cell therapy IMA203 this year in light of the response and ...
With Kezar in lupus limbo, Concentra spies potential acquisition
Oct 9, 2024 · With Kezar Life Sciences’ lupus plans up in the air while the company investigates patient deaths, Concentra Biosciences has spied an opportunity to scoop up another troubled biotech.